Effects of the α 1a-Adrenoceptor Antagonist RS-17053 on Phenylpropanolamine-Induced Anorexia in Rats

• Published in: Pharmacology, biochemistry and behavior Vol. 57; no. 1; pp. 281 - 284
• Main Authors: Wellman, P.J., McMAHON, L.R., Green, T., Tole, A.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 1997
• Subjects: Anorexia; Phenylpropanolamine; Prazosin; RS-17053; α1-Adrenergic receptors; Prazosin; Anorexia; RS-17053; α1-Adrenergic receptors; Phenylpropanolamine
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/S0091-3057(96)00351-6

Activation of α1-Adrenergic receptors via systemic administration of drugs such as phenylpropanolamine (PPA) and cirazoline results in the suppression of feeding in rats. Whether PPA acts via activation of the three currently identified α1-Adrenoceptor subtypes is unknown. The intent of the present study was thus to examine the effects of systemic administration of the novel α 1a-Adrenoceptor antagonist RS-17053 on PPA-induced anorexia. Adult male rats ( n=6 to 8 per group) were pretreated (IP) with either 0, 0.1, 0.5, 2.5, or 10.0 mg/kg RS-17053 or with 2.0 mg/kg of the prototypical α1-Adrenoceptor antagonist prazosin. Five minutes later, each rat was treated (IP) with either 0, 5, 10 or 15 mg/kg PPA. Food and water intakes were recorded for a 30 min period starting 10 min after the treatment injection. Rats pretreated with vehicle and then treated with PPA exhibited a dose-dependent suppression of feeding with a maximal effect evident at the 15 mg/kg dose of PPA. Pretreatment with 2.0 mg/kg prazosin reversed the anorexic activity of PPA. Pretreatment with RS-17053 (0.1–2.5 mg/kg) did not alter either baseline feeding or the anorexic action of PPA. These results suggest that PPA does not act via the α 1a-Adrenergic receptor subtype to suppress food intake.